Close Menu

Invitrogen, Norgen Bioteck

Premium
Invitrogen launched its OptiCHO Express kit last week, designed “for the efficient growth and transfection of dihydrofolate reductase-deficient Chinese hamster ovary DG44 cells in suspension culture,” the company said.
 
The kit provides a complete workflow protocol for developing stable cell lines and includes components for expression vector construction, high-efficiency transfection of DG44 cells, and combinant protein expression in a serum-free environment with animal-free media, Invitrogen said.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

NPR reports the US Food and Drug Administration has approved a treatment for a genetic disorder that causes rapid aging.

Late-stage testing indicates the AstraZeneca and Oxford University SARS-CoV-2 vaccine can have up to 90 percent efficacy, the Associated Press reports.

ScienceInsider reports Nature Communications is reviewing a paper on mentorship following social media criticism arguing it is sexist.

In PLOS this week: method to account for sequencing errors in phylogenies, study of influenza A in Switzerland, and more.